Active Stock Evaluation: Jaguar Health, Inc. (NASDAQ:JAGX)

Jaguar Health, Inc. (NASDAQ:JAGX) with the stream of 9.02% in the last hour of trading session.

Jaguar Health, Inc. (JAGX) shares jumped 9.02% to close at $3.68. About 22,550,289 million shares traded hands on 54.01M trades for the day, compared with an average daily volume of 54.01M shares out of a total float of 63.07M. After opening the trading day at $3.84, shares of Jaguar Health, Inc. stayed within a range of $3.45 to $3.85.

With today’s gains, Jaguar Health, Inc. now has a market cap of $242.28M. Shares of Jaguar Health, Inc. have been trading within a range of $0.18 and $4.47 over the last year, and it had a 50-day SMA of $432.67% and a 200-day SMA of $595.06%.

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for various indications, including cholera. The company’s animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, its products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E ratio. Last traded has a PEG ratio of 0 where as its P/E ratio was 0. The overall volume in the last trading session was 22,550,289 shares.

Important Results:

Jaguar Health, Inc. has P/S value of 29.19 while its P/B esteem remains at 67.60. Likewise, the company has Return on Assets of -98.40%, Return on Equity of -853.40% and Return on Investment of -208.00%. The company demonstrates Gross Margin and Operating Margin of 61.10% and 0 respectively.

JAGX’s price to sales ratio for trailing twelve months was 29.19 and price to book ratio for most recent quarter was 67.60, whereas price to cash per share for the most recent quarter was 186.37. The Company’s price to free cash flow for trailing twelve months was recorded as 0.

Historical Performances to Consider:

The Stock’s performances for Monthly, weekly, half-yearly, quarterly & year-to-date are mentioned below:-

On a Monthly basis the stock was 906.55%. On a weekly basis, the stock remained 73.33%. The half-yearly performance for the stock has 439.42%, while the quarterly performance was 969.96%. Looking further out we can see that the stock has moved 314.72% over the year to date. Other technical indicators are worth considering in assessing the prospects for EQT. RSI for instance was stand at 79.30.

Jake Charles

About Jake Charles

This is Jake Charles, a Senior News Writer for “Stocks Equity”. I covers “Active Stocks” sector and writes about trending Active Hot companies from an exclusive and “out of the box” perspective. I worked independently as a self motivator and with the financial institute as financial adviser to invest in the Active sector for over 9 years in the developing countries by introducing new phases and ways to improve in this sector. I like to travel all over the globe to get new experience and provide by best services to the companies. As an advisor I like to work with new people to share and explore new ideas keeping in view minimizing the operating cost and giving the best final product through new technology and minimizing the time of development.

View all posts by Jake Charles →

Leave a Reply

Your email address will not be published. Required fields are marked *